Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
5 Breakout Stars in Ongoing television Series - 210 Demonstrated Tips to Boost Your New Android Cell phone: A Thorough Aide
- 3Sound Propensities: 20 Methods for helping Your Insusceptible Framework
- 4Roman around the Christmas tree | Space photo of the day for Dec. 25, 2025
- 5Who is Adm. Frank 'Mitch' Bradley and what does he have to do with the Venezuela boat strikes?
- Fears of global aluminum shortages intensify
- Like many holiday traditions, lighting candles and fireplaces is best done in moderation
- 'Wicked: For Good' was filmed at this surreal National Park in Egypt
- German state railway loss widens, passengers warned of trouble ahead
- Well informed: How to Take full advantage of Your Gadgets
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- After fleeing past Hezbollah fighting, some Israelis on northern border vow to stay
- Carry Nature Inside with These Staggering Plant Decisions
- Curl Up With Some Hot Chocolate And Watch Mighty Car Mods Explore Japan In A Honda City Turbo II
